IncobotulinumtoxinA for Aesthetic Treatments: Review and Recommendations From Latin America.

As new aesthetic treatment techniques are developed, the understanding of botulinum toxin type A safety and treatment outcomes continues to evolve. This article was developed to provide a comprehensive up-to-date reference for clinicians using incobotulinumtoxinA (INCO; Xeomin/Bocouture, Merz Pharmaceuticals GmbH, Frankfurt, Germany) for aesthetic treatments. A Latin American panel of 11 physicians was assembled to discuss and develop recommendations on the use of INCO for aesthetic treatment based on the literature review and their private medical practice. The panel found that INCO is a highly purified botulinum toxin, without other clostridial proteins (hemagglutinins and nonhemagglutinins). IncobotulinumtoxinA has proven its efficacy and duration over time, maintaining response after multiple treatment cycles. This recommendation provides up-to-date information on the use of INCO for aesthetic treatment, focusing on the differential properties of this product regarding its purity, performance, customization, and patient satisfaction. Copyright © 2024 by the American Society for Dermatologic Surgery, Inc. Published by Wolters Kluwer Health, Inc. All rights reserved.

Citation

Carla de Sanctis Pecora, Ada Trindade de Almeida, Vinicius Figueredo, Cyro Hirano, Alejandra Bugallo, Cristina Cortés, Esperanza C Welsh, Julieta Spada, Nicolás Heredia, Victoria de La Fuente, Mariana Muniz. IncobotulinumtoxinA for Aesthetic Treatments: Review and Recommendations From Latin America. Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 2024 Sep 01;50(9S):S24-S34

Mesh Tags

Substances

PMID: 39196830

search → result